PortalPublikationenTransfer of minimally manipulated CMV-specific T cells from ...

Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT

Standard

Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. / Neuenhahn, M; Albrecht, J; Odendahl, M; Schlott, F; Dössinger, G; Schiemann, M; Lakshmipathi, S; Martin, K; Bunjes, D; Harsdorf, S; Weissinger, E M; Menzel, H; Verbeek, M; Uharek, L; Kröger, N; Wagner, E; Kobbe, G; Schroeder, T; Schmitt, M; Held, G; Herr, W; Germeroth, L; Bonig, H; Tonn, T; Einsele, H; Busch, D H; Grigoleit, G U.

in: LEUKEMIA, Jahrgang 31, Nr. 10, 10.2017, S. 2161-2171.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Neuenhahn, M, Albrecht, J, Odendahl, M, Schlott, F, Dössinger, G, Schiemann, M, Lakshmipathi, S, Martin, K, Bunjes, D, Harsdorf, S, Weissinger, EM, Menzel, H, Verbeek, M, Uharek, L, Kröger, N, Wagner, E, Kobbe, G, Schroeder, T, Schmitt, M, Held, G, Herr, W, Germeroth, L, Bonig, H, Tonn, T, Einsele, H, Busch, DH & Grigoleit, GU 2017, 'Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT', LEUKEMIA, Jg. 31, Nr. 10, S. 2161-2171. https://doi.org/10.1038/leu.2017.16

APA

Neuenhahn, M., Albrecht, J., Odendahl, M., Schlott, F., Dössinger, G., Schiemann, M., Lakshmipathi, S., Martin, K., Bunjes, D., Harsdorf, S., Weissinger, E. M., Menzel, H., Verbeek, M., Uharek, L., Kröger, N., Wagner, E., Kobbe, G., Schroeder, T., Schmitt, M., ... Grigoleit, G. U. (2017). Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. LEUKEMIA, 31(10), 2161-2171. https://doi.org/10.1038/leu.2017.16

Vancouver

Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dössinger G, Schiemann M et al. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. LEUKEMIA. 2017 Okt;31(10):2161-2171. https://doi.org/10.1038/leu.2017.16

Bibtex

@article{7fb9dcca906c4400b999bbcccc13531f,
title = "Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT",
abstract = "Cytomegalovirus (CMV) infection is a common, potentially life-threatening complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). We assessed prospectively the safety and efficacy of stem cell-donor- or third-party-donor-derived CMV-specific T cells for the treatment of persistent CMV infections after allo-HSCT in a phase I/IIa trial. Allo-HSCT patients with drug-refractory CMV infection and lacking virus-specific T cells were treated with a single dose of ex vivo major histocompatibility complex-Streptamer-isolated CMV epitope-specific donor T cells. Forty-four allo-HSCT patients receiving a T-cell-replete (D(+) repl; n=28) or T-cell-depleted (D(+) depl; n=16) graft from a CMV-seropositive donor were screened for CMV-specific T-cell immunity. Eight D(+) depl recipients received adoptive T-cell therapy from their stem cell donor. CMV epitope-specific T cells were well supported and became detectable in all treated patients. Complete and partial virological response rates were 62.5% and 25%, respectively. Owing to longsome third-party donor (TPD) identification, only 8 of the 57 CMV patients transplanted from CMV-seronegative donors (D(-)) received antigen-specific T cells from partially human leukocyte antigen (HLA)-matched TPDs. In all but one, TPD-derived CMV-specific T cells remained undetectable. In summary, adoptive transfer correlated with functional virus-specific T-cell reconstitution in D(+) depl patients. Suboptimal HLA match may counteract expansion of TPD-derived virus-specific T cells in D(-) patients.Leukemia advance online publication, 17 February 2017; doi:10.1038/leu.2017.16.",
keywords = "Journal Article",
author = "M Neuenhahn and J Albrecht and M Odendahl and F Schlott and G D{\"o}ssinger and M Schiemann and S Lakshmipathi and K Martin and D Bunjes and S Harsdorf and Weissinger, {E M} and H Menzel and M Verbeek and L Uharek and N Kr{\"o}ger and E Wagner and G Kobbe and T Schroeder and M Schmitt and G Held and W Herr and L Germeroth and H Bonig and T Tonn and H Einsele and Busch, {D H} and Grigoleit, {G U}",
year = "2017",
month = oct,
doi = "10.1038/leu.2017.16",
language = "English",
volume = "31",
pages = "2161--2171",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "10",

}

RIS

TY - JOUR

T1 - Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT

AU - Neuenhahn, M

AU - Albrecht, J

AU - Odendahl, M

AU - Schlott, F

AU - Dössinger, G

AU - Schiemann, M

AU - Lakshmipathi, S

AU - Martin, K

AU - Bunjes, D

AU - Harsdorf, S

AU - Weissinger, E M

AU - Menzel, H

AU - Verbeek, M

AU - Uharek, L

AU - Kröger, N

AU - Wagner, E

AU - Kobbe, G

AU - Schroeder, T

AU - Schmitt, M

AU - Held, G

AU - Herr, W

AU - Germeroth, L

AU - Bonig, H

AU - Tonn, T

AU - Einsele, H

AU - Busch, D H

AU - Grigoleit, G U

PY - 2017/10

Y1 - 2017/10

N2 - Cytomegalovirus (CMV) infection is a common, potentially life-threatening complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). We assessed prospectively the safety and efficacy of stem cell-donor- or third-party-donor-derived CMV-specific T cells for the treatment of persistent CMV infections after allo-HSCT in a phase I/IIa trial. Allo-HSCT patients with drug-refractory CMV infection and lacking virus-specific T cells were treated with a single dose of ex vivo major histocompatibility complex-Streptamer-isolated CMV epitope-specific donor T cells. Forty-four allo-HSCT patients receiving a T-cell-replete (D(+) repl; n=28) or T-cell-depleted (D(+) depl; n=16) graft from a CMV-seropositive donor were screened for CMV-specific T-cell immunity. Eight D(+) depl recipients received adoptive T-cell therapy from their stem cell donor. CMV epitope-specific T cells were well supported and became detectable in all treated patients. Complete and partial virological response rates were 62.5% and 25%, respectively. Owing to longsome third-party donor (TPD) identification, only 8 of the 57 CMV patients transplanted from CMV-seronegative donors (D(-)) received antigen-specific T cells from partially human leukocyte antigen (HLA)-matched TPDs. In all but one, TPD-derived CMV-specific T cells remained undetectable. In summary, adoptive transfer correlated with functional virus-specific T-cell reconstitution in D(+) depl patients. Suboptimal HLA match may counteract expansion of TPD-derived virus-specific T cells in D(-) patients.Leukemia advance online publication, 17 February 2017; doi:10.1038/leu.2017.16.

AB - Cytomegalovirus (CMV) infection is a common, potentially life-threatening complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). We assessed prospectively the safety and efficacy of stem cell-donor- or third-party-donor-derived CMV-specific T cells for the treatment of persistent CMV infections after allo-HSCT in a phase I/IIa trial. Allo-HSCT patients with drug-refractory CMV infection and lacking virus-specific T cells were treated with a single dose of ex vivo major histocompatibility complex-Streptamer-isolated CMV epitope-specific donor T cells. Forty-four allo-HSCT patients receiving a T-cell-replete (D(+) repl; n=28) or T-cell-depleted (D(+) depl; n=16) graft from a CMV-seropositive donor were screened for CMV-specific T-cell immunity. Eight D(+) depl recipients received adoptive T-cell therapy from their stem cell donor. CMV epitope-specific T cells were well supported and became detectable in all treated patients. Complete and partial virological response rates were 62.5% and 25%, respectively. Owing to longsome third-party donor (TPD) identification, only 8 of the 57 CMV patients transplanted from CMV-seronegative donors (D(-)) received antigen-specific T cells from partially human leukocyte antigen (HLA)-matched TPDs. In all but one, TPD-derived CMV-specific T cells remained undetectable. In summary, adoptive transfer correlated with functional virus-specific T-cell reconstitution in D(+) depl patients. Suboptimal HLA match may counteract expansion of TPD-derived virus-specific T cells in D(-) patients.Leukemia advance online publication, 17 February 2017; doi:10.1038/leu.2017.16.

KW - Journal Article

U2 - 10.1038/leu.2017.16

DO - 10.1038/leu.2017.16

M3 - SCORING: Journal article

C2 - 28090089

VL - 31

SP - 2161

EP - 2171

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 10

ER -